Associated Papers
Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.
Xu M et al.
The Journal of Pharmacology and Experimental Therapeutics, 2017
Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities.
Yamazaki H et al.
Biochemical Pharmacology, 2013
Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.
Yeung CK et al.
Archives of Biochemistry and Biophysics, 2007
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.
Cashman JR
Drug Discovery Today, 2004
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.
Cashman JR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2002
Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity.
Störmer E et al.
British Journal of Clinical Pharmacology, 2000
Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication.
Treacy EP et al.
Human Molecular Genetics, 1998
Select a paper to view details